Operates in the pharmaceuticals and biotechnology space, reporting standalone revenue from operations of Rs 768.73 crore in FY26 against Rs 644.47 crore the year before and consolidated net profit of Rs 102.78 crore. The business carries out in-house Research and Development, with its R&D unit receiving renewal of the government's DSIR recognition in 2026. Operations extend overseas through a wholly-owned German subsidiary, Venus Pharma GmbH, which is currently undergoing restructuring with parent support pledged; the auditor has flagged Rs 28.60 crore of share application money outstanding at this subsidiary. The cost base is dominated by materials, which absorb 50.4% of revenue, while employees account for 11.5% and other operating expenses for 19.0%, leaving an EBITDA margin of 20.77% in FY26. The Board has recommended revisions to the Memorandum of Association to expand the company's stated scope into biotechnology, digital and telehealth businesses, subject to shareholder approval at the 37th AGM on August 20, 2026. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceuticals (existing operations), Biotechnology, digital and telehealth (proposed scope). Pharmaceuticals with in-house R&D and overseas subsidiary exposure
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 599 | 556 | 601 | 648 | 770 |
| EBITDA (ex other income) | 62 | 60 | 60 | 73 | 147 |
| margin % | 10.4 | 10.8 | 9.9 | 11.3 | 19.1 |
| Owners' profit | 0 | 0 | 27 | 45 | 0 |
| EPS, as reported (₹) | 30.86 | 19.88 | 21.31 | 33.90 | 76.89 |
| ROE % · ROCE % | 9.2 · 7.6 | 5.8 · 7.4 | 5.8 · 8.2 | 8.1 · 12.4 | 15.5 · 19.4 |
| Debt / equity (x) | 0.10 | 0.09 | 0.08 | 0.00 | 0.00 |
| Cash from operations | 41 | 37 | 37 | 86 | 156 |
| Capex | (14) | (8) | (9) | (10) | (38) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 167 | 177 | 195 | 132 | 193 | 180 | 259 | 179 |
| Profit before tax | 9 | 25 | 31 | 13 | 26 | 33 | 62 | 30 |
| Net profit | 4 | 20 | 21 | 10 | 20 | 26 | 47 | 23 |
| EPS (₹) | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.53 | 17.18 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · Newspaper notice to physical shareholders on share transfer window | compliance | minimal | — | — |
| 9 Sept 2026 · Newspaper notice to physical shareholders on share transfer | compliance | minimal | — | — |
| 8 Sept 2026 · Special window for re-lodgement of physical share transfer requests | compliance | minimal | — | — |
| 7 Sept 2026 · Social media awareness on SEBI special window for physical share transfers | compliance | minimal | — | — |
| 21 Aug 2026 · Venus Remedies 37th AGM: All 12 resolutions passed, Rs.10 dividend declared | board shareholder meetings | low | — | — |
| 21 Aug 2026 · Venus Remedies: Shareholders approve new MOA and AOA | general | low | — | — |
| 21 Aug 2026 · 37th AGM: All 12 resolutions passed; Rs.10 dividend declared | board shareholder meetings | low | — | — |
| 20 Aug 2026 · Board appointments and re-appointments approved at AGM | management changes | medium | — | — |
| 20 Aug 2026 · 37th AGM held; 100 percent dividend declared; key director appointments | board shareholder meetings | low | — | — |
| 4 Aug 2026 · Social media posts on special window for re-lodgement of physical share transfers | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 18.5 | 28.9 | 53 of 169 | 69% |
| P/B | 3.3 | 3.3 | 81 of 163 | 51% |
| ROCE | 19.4 | 10.8 | 36 of 183 | 81% |
| ROE | 15.5 | 10.4 | 48 of 171 | 72% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 20.6 | 17.5 | 72 of 165 | 57% |
| Revenue growth | 35.6 | 16.3 | 37 of 161 | 78% |
| Profit growth | 139.3 | 30.9 | 31 of 158 | 81% |
| Market cap | 2154 | 839 | 78 of 182 | 58% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
